Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
Vertex (VRTX) Kaftrio Gets Europe Nod for CF in Children
12:19pm, Wednesday, 12'th Jan 2022
The European Commission approves Vertex's (VRTX) triple combination therapy, Kaftrio, in combination with Kalydeco for treating cystic fibrosis in children aged between six and 11 years.
Is Vertex (VRTX) a Solid Growth Stock? 3 Reasons to Think " Yes "
01:50pm, Tuesday, 11'th Jan 2022
Vertex (VRTX) could produce exceptional returns because of its solid growth attributes.
EC approves Vertex''s Kaftrio + ivacaftor for cystic fibrosis in children aged 6 to 11 years
10:14am, Tuesday, 11'th Jan 2022 Seeking Alpha
Vertex Pharmaceuticals (VRTX) announces that the European Commission ((EC)) has granted approval for the label extension of KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in a
Vertex Pharma: EU Oks KAFTRIO In Combination With Ivacaftor To Treat Children With Cystic Fibrosis
08:53am, Tuesday, 11'th Jan 2022 Business Insider Markets
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) announced Tuesday that the European Commission has granted approval for the label extension of KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor. The approval is for the treatment of cystic fibrosis or CF in patients ages 6 through 11 years old who have at least one
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
07:09pm, Monday, 10'th Jan 2022
Vertex Pharmaceuticals (VRTX) closed at $223.96 in the latest trading session, marking a +0.95% move from the prior day.
Vertex Pharmaceuticals (VRTX) CEO, Reshma Kewalramani Presents at 40th Annual JP Morgan Healthcare Conference - Conference Call Transcript
3 No-Brainer Big Pharma Stocks to Buy in 2022
09:27am, Sunday, 09'th Jan 2022
There's a lot to like about each of these companies.
Biotech Stocks Are Due to Bounce Back. Vertex Pharmaceuticals Stands Out.
02:15am, Saturday, 08'th Jan 2022 Barron''s
Vertex Pharmaceuticals had a miserable 2021, dropping 7.1% and underperforming the large-cap iShares Biotech ETF by about eight percentage points. This year is already looking better.
Better Buy: Vertex Pharmaceuticals vs. Biogen
06:37am, Friday, 07'th Jan 2022
In this battle of biotech giants, one emerges as the clear winner.
A Bullish Sign Appears On Vertex Pharmaceuticals''s Chart
03:12pm, Thursday, 06'th Jan 2022 Benzinga
If history is any guide, there may be good fortune ahead for Full story available on Benzinga.com
Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
04:05pm, Tuesday, 04'th Jan 2022
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 202
Vertex Pharmaceuticals Stock: Bull vs. Bear
07:03am, Friday, 31'st Dec 2021
Here are two differeing views on the big biotech stock.
2 Unstoppable Stocks That Could Go Parabolic
08:00am, Thursday, 30'th Dec 2021
It's not too late to snag these stocks before they go skyward.
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
07:09pm, Wednesday, 29'th Dec 2021
Vertex Pharmaceuticals (VRTX) closed at $223.32 in the latest trading session, marking a +0.63% move from the prior day.
3 Biotech Stocks That Sank in 2021 but Could Soar in 2022
09:31am, Sunday, 26'th Dec 2021
These stocks could rebound nicely in the new year.
